ESMO Breast 2022 | Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBC

Benedetta Conte, IDIBAPS, Barcelona, Spain, talks on a Phase II trial investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2-positive (HER2+) early breast cancer, demonstrating a 51% pathologic complete response (pCR) rate and a favorable safety profile. This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.